TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04592432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SIGN@L-A
Description: Two prototypes of a serious game were developed as part of this study. The design of these prototypes is based on the conceptual model by Alexiou and Schippers (2018) linking the instructional design of a serious game to intrinsic motivation, engagement, and learning outcomes. The design of SIGN@L-A will include all elements of the serious game instructional design proposed by these authors which are game mechanics (i.e., objectives to meet, feedback, and rewards), a narrative (i.e., a protagonist, non-playable characters, and narrative events), and aesthetics (i.e., functional and hedonic aesthetics).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SIGN@L-A
Description: Two prototypes of a serious game were developed as part of this study. The design of these prototypes is based on the conceptual model by Alexiou and Schippers (2018) linking the instructional design of a serious game to intrinsic motivation, engagement, and learning outcomes. The design of SIGN@L-A will include all elements of the serious game instructional design proposed by these authors which are game mechanics (i.e., objectives to meet, feedback, and rewards), a narrative (i.e., a protagonist, non-playable characters, and narrative events), and aesthetics (i.e., functional and hedonic aesthetics).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SIGN@L-B
Description: The design of SIGN@L-B will include only some of these elements which are some of the game mechanics (i.e., objectives to meet, limited feedback), and a functional aesthetic.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SIGN@L-B
Description: The design of SIGN@L-B will include only some of these elements which are some of the game mechanics (i.e., objectives to meet, limited feedback), and a functional aesthetic.
Study: NCT00863837

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: terlipressin (vasoconstrictor)
Description: Ligation plus terlipressin 1mg q6h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoloc (proton pump inhibitor)
Description: Pantoloc infusion (1 vial q.d.); Using pantoloc to reduce rebleed after EVL
Study: NCT03836976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory gamma sensory stimulation
Description: Gamma-conditioning stimulation will be~administered in 2 blocks of 3 min each. During each block, participants will be presented with a continuous~tone at the CF (500 or 1200 Hz) that will be amplitude modulated at 40 H
Study: NCT01743339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy for Insomnia(4 individual therapy sessions over 5 weeks) will consist of a standard, structured, multi-component CBT intervention (sleep education, sleep hygiene, sleep restriction, stimulus control, cognitive therapy, and relapse prevention) Cognitive Processing Therapy will consist of a standard, structured 12-session protocol (PTSD education, exploring personal impact of trauma, experiencing emotions related to thoughts of trauma, cognitive therapy, and applying healthy thoughts and behaviors) delivered in individual weekly sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Cognitive Processing Therapy will consist of a standard, structured 12-session protocol (PTSD education, exploring personal impact of trauma, experiencing emotions related to thoughts of trauma, cognitive therapy, and applying healthy thoughts and behaviors) delivered in individual weekly sessions.
Study: NCT05148585

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy
Description: Patients get physiotherapy intervention after the surgery. exercises are progressive. sessions start passive range of motion exercises for 5 weeks while they are using a static dorsal splint. then splints are removed and patients start active range of motion exercises. and exercises progress to blocking, tendon gliding and resistive exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: Patients get physiotherapy intervention after the surgery. exercises are progressive. sessions start passive range of motion exercises for 5 weeks while they are using a static dorsal splint. then splints are removed and patients start active range of motion exercises. and exercises progress to blocking, tendon gliding and resistive exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: activity-based therapy
Description: patients get from the seventh week to the twelfth week an activity-based therapy. Activities are diverse according to the patient's needs. activities have therapeutic efficacy for improving range of motion, tendon gliding and strength.
Study: NCT00195260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosutinib
Description: Dose levels evaluated 50mg, 100mg, 200mg, 300mg, 400mg, 500mg and 600mg. 500mg was identified as MTD, however due to GI toxicities at that dose, 400mg was selected as the RP2D. Drug was administered as long as tolerable and disease under study did not worsen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosutinib
Description: 400mg QD bosutinib, as long as tolerated and disease under study does not worsen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosutinib
Description: 400mg QD bosutinib, as long as tolerated and disease under study does not worsen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosutinib
Description: 400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
Study: NCT02049866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months
Study: NCT04024631

Intervention type: OTHER
Group type: OTHER
Intervention: 75g glucose beverage (Glucola, Trutol, or similar brand)
Description: Subjects will present fasting to the study day and ingest the glucose beverage during the oral glucose tolerance test.
Study: NCT01882998

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended repeat HIV testing and enhanced counseling
Description: Pregnant/breastfeeding women in the intervention arm and their male partners if present will receive extended repeat HIV testing and enhanced counseling around the time of labor and delivery and throughout the breastfeeding period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended repeat HIV testing and enhanced counseling
Description: Pregnant/breastfeeding women in the intervention arm and their male partners if present will receive extended repeat HIV testing and enhanced counseling around the time of labor and delivery and throughout the breastfeeding period.
Study: NCT03559244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic compression brace
Description: custom-fitted brace adjusts the pressure on the thoracic wall and enables lateral expansion of the thorax

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic compression brace
Description: custom-fitted brace adjusts the pressure on the thoracic wall and enables lateral expansion of the thorax

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: posture exercises, deep breathing exercises, exercises for manipulation and mobilization of ribs, and core exercises
Study: NCT04024631

Intervention type: OTHER
Group type: OTHER
Intervention: DXA, whole body
Description: Subjects will undergo a whole body DXA scan for assessment of adiposity index and body fat distribution.
Study: NCT00269516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pardoprunox
Description: fixed dose 6 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pardoprunox
Description: fixed dose 12 mg
Study: NCT03559244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: posture exercises, deep breathing exercises, exercises for manipulation and mobilization of ribs, and core exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: posture exercises, deep breathing exercises, exercises for manipulation and mobilization of ribs, and core exercises
Study: NCT03119116

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Oral direct factor Xa inhibitors, 15mg and 20mg tablets QD

Intervention type: DRUG
Intervention: Dabigatran
Description: Oral direct thrombin inhibitors, 75mg and 150mg capsules BID

Intervention type: DRUG
Intervention: Apixaban
Description: Oral direct factor Xa inhibitors, 2.5mg and 5 mg tablets BID
Study: NCT03860311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bladder Ultrasound
Description: Bladder fullness will be assessed upon enrollment and if not full, the patient will receive hydration, determined by treating physician, and the bladder ultrasound will be repeated every 30 minutes until the patient states that the bladder is full, or until bladder is deemed full based on a previously validated bladder fullness qualitative scale, at which point patients in this group will proceed to undergo pelvic ultrasound.
Study: NCT02327793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Study: NCT03860311

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Per institution protocol, patients in the standard of care group will have urethral (bladder) catheter placed immediately after the order for pelvic ultrasound and will undergo retrograde bladder filling as determined by the radiologist/ultrasonographer to the point necessary to fully visualize pelvic structures.
Study: NCT00269516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pardoprunox
Description: 12-42mg
Study: NCT01886131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Synchronised video-polysomnography
Description: We will record the electrical activity of the STN (local field potentials) during the 2 consecutive nights following the implantation of the electrodes in the STN for DBS. In this period, the deep brain stimulator will not yet be connected to the intracranial electrodes.~The intracranial EEG signal from the STN will be synchronised with the scalp EEG and other video-polysomnographic parameters.~The STN recordings during the phasic movements of RBD will be compared to the recordings obtained at the same level during a motor task.
Study: NCT03118531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System(34/38 mm)
Description: The stenting procedure should be performed according to the Instructions for Use that is provided with each 34/38 mm Resolute Integrity stent.
Study: NCT03734367

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emotional abilities training program
Description: A randomized controlled trial that evaluates the effectiveness of a program of emotional skills on metabolic control to be assessed through the glycosylated hemoglobin (HbA1c), healthy lifestyle habits and wellbeing in adolescents with type 1, Diabetes Mellitus
Study: NCT00269516

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00641654

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa-2a and ribavirin
Description: Arm A: Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 48 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa-2a and ribavirin
Description: Arm B:Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 48 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 48 weeks
Study: NCT02327793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Labetalol
Study: NCT02611011

Intervention type: DEVICE
Intervention: Congo Red Test (GV-005)
Description: The GV-005 is a simple test has been developed to detect unfolded or misfolded proteins in urine.
Study: NCT02380079

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SCD-101
Description: Administered as gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCD-101
Description: Administered as gelatin capsules
Study: NCT00641654

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa-2a and ribavirin
Description: Arm C:Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 24 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 24 weeks
Study: NCT03426683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intestinal Microbiota Transplantation
Description: the bacteria will be transplanted to mid-gut by nose-jejunum nutrition tube. Patients in this study will be assigned to receive standardized IMT three times or traditional medicine and would be followed up for at least 3 year.
Study: NCT04530513

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy - Level 1
Description: 6Gy x 2 fractions to all sites in 2 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy - Level 2
Description: 6Gy x 3 fractions to all sites in 3 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy - Level 3
Description: 6Gy x 4 fractions to all sites in 4 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy - Level 4
Description: 6Gy x 5 fractions to all sites in 5 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy - De-escalation Level
Description: 6Gy x 1 fraction to all sites in 1 week
Study: NCT02783235

Intervention type: OTHER
Group type: OTHER
Intervention: cervical cancer screening
Description: for 50 ANMs/ASHAs/PHWs/ in conducting cervical cancer related health education , screening for cervical cancers using VIA, collection of PAP smears and HPV samples.
Study: NCT02828423

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EMD
Description: Regenerative surgery with EMD

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EMD
Description: Regenerative surgery with EMD
Study: NCT02679313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phoropter
Description: Each subject will be tested on 3 separate occasions using either the manual phoropter (American Optical 11625), electronic phoropter (Topcon CV-5000) or the wearable adaptive refractor (VisionFit). Oculomotor measurements, i.e., heterophoria, vergence ranges, AC/A and accommodative findings will be measured at each session using the different devices. Each session will be separated by a minimum of 24 hours and a maximum of 14 days.
Study: NCT02828423

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BC
Description: Regenerative surgery with BC
Study: NCT02873728

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning
Description: Creation of Brief 5 min Ischemia to upper limb using a Blood pressure cuff

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Puting blood pressure cuff on upper limb and inflating to 10mmhg for 5 min
Study: NCT04955041

Intervention type: OTHER
Intervention: MRI
Description: T2\* MRI
Study: NCT03084770

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiological imaging studies
Description: Patients will be submitted to radiological imaging studies (CT scan and/or MRI and/ or 68Gallium PET/CT and/or Octreoscan and/or EUS+FNAand/or Octreoscan and/or EUS+FNA) at diagnosis, and then every 6 months for the first two years and yearly thereafter for five years in the absence of significant changes on imaging or symptoms appearance. Every 12 months (or 6 months for patients with Ki67\> 2%) a high quality imaging (CT scan or MRI) is required.

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiological imaging studies
Description: Patients will be submitted to radiological imaging studies (CT scan and/or MRI and/ or 68Gallium PET/CT and/or Octreoscan and/or EUS+FNAand/or Octreoscan and/or EUS+FNA) at diagnosis, and then every 6 months for the first two years and yearly thereafter for five years in the absence of significant changes on imaging or symptoms appearance. Every 12 months (or 6 months for patients with Ki67\> 2%) a high quality imaging (CT scan or MRI) is required.
Study: NCT04523441

Intervention type: OTHER
Intervention: Focus group
Description: Holding of a focus group by a sociologist

Intervention type: OTHER
Intervention: Semi-directive interview
Description: Conducting a semi-directive interview by a sociologist after discharge from hospital
Study: NCT03084770

Intervention type: OTHER
Intervention: Quality of Life Assessment
Description: quality of life and the perceived burden of surveillance or follow-up after surgery for participants, will be investigated by administrating HADS questionnaire and EORTC QLQ-C30 (version 3) and EORTC QLQ-GI.NET21 Module.

Intervention type: OTHER
Intervention: Quality of Life Assessment
Description: quality of life and the perceived burden of surveillance or follow-up after surgery for participants, will be investigated by administrating HADS questionnaire and EORTC QLQ-C30 (version 3) and EORTC QLQ-GI.NET21 Module.
Study: NCT04488796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assigned Strategies: Opt-in
Description: Participants will be assigned two behavioural strategies with the opt-in choice structure

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assigned Strategies: Active Choice
Description: Participants will be assigned two behavioural strategies with the Active choice structure

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assigned Strategies: Enhanced Active Choice
Description: Participants will be assigned two behavioural strategies with the Enhanced Active choice structure

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice of Assignment: Opt-in
Description: Participants will have the choice to be assigned strategies or to manage their own strategies. The strategies will be assigned using the Opt-in choice structure

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice of Assignment: Active Choice
Description: Participants will have the choice to be assigned strategies or to manage their own strategies. The strategies will be assigned using the Active choice structure

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice of Assignment: Enhanced Active Choice
Description: Participants will have the choice to be assigned strategies or to manage their own strategies. The strategies will be assigned using the Enhanced Active choice structure
Study: NCT03760848

Intervention type: DRUG
Group type: OTHER
Intervention: Aramchol
Description: Aramchol 600 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: Midazolam 2 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: atorvastatin 40 mg
Study: NCT01294891

Intervention type: OTHER
Intervention: Imaging
Description: Contrast ultrasound perfusion imaging and complete echocardiography

Intervention type: OTHER
Intervention: Imaging
Description: Contrast ultrasound perfusion imaging and complete echocardiography

Intervention type: OTHER
Intervention: Imaging
Description: Contrast ultrasound perfusion imaging and complete echocardiography
Study: NCT02242994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynavox Maestro
Description: Receives commercially available communication device Dynavox Maestro to test speed and quality of communication.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental App
Description: Participant receives experimental app to test speed and error rate of communication.
Study: NCT02001116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality Improvement intervention
Description: 1. Training for local trainers and medical staff on the National Adaptation of the WHO guidelines Pocket Book of Hospital Care for Children.~2. Regular supporting supervision and monitoring at hospital level aimed at a sustainable improvement of the quality of the paediatric hospital care
Study: NCT04229498

Intervention type: DRUG
Intervention: Monotherapy and combination therapy (all antibiotics that are given by attending pysicians and can be active against Klebsiella pneumoniae will be evaluated)
Description: In carbapenem heteroresistant Klebsiella pneumoniae group, carbapenem monotherapy (ertapenem, imipenem, meropenem) vs other treatment groups will also be compared

Intervention type: DRUG
Intervention: Monotherapy and combination therapy (all antibiotics that are given by attending pysicians and can be active against Klebsiella pneumoniae will be evaluated)
Description: In carbapenem heteroresistant Klebsiella pneumoniae group, carbapenem monotherapy (ertapenem, imipenem, meropenem) vs other treatment groups will also be compared
Study: NCT02153450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: Undergo stereotactic radiosurgery
Study: NCT00715611

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pleurectomy/Decortication
Description: Pleurectomy/decortication will be performed as per standard technique

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed and cisplatin or carboplatin
Description: The combination of pemetrexed and cisplatin or carboplatin will be given every 3 weeks for up to 4 cycles. Pemetrexed will be administered at 500mg/m2 as a 10-minute infusion. Cisplatin will be administered at 75mg/m2 as a 60-minute infusion. Carboplatin will be administered at an AUC of 5 over 30 minutes. Chemotherapy may be administered in the neoadjuvant or adjuvant setting.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: IMRT will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions with an optional SIB to gross residual disease (pending meeting normal tissue constraints).
Study: NCT00338858

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: walking and balance performance evaluation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walking and balance performance evaluation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walking and balance performance evaluation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: muscle strength, walking and balance performance
Description: HHD- muscle strength, Balance performance - TUG, FRT, Walking performance- gaiterite and 2 min walk test

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: muscle strength, walking and balance performance
Description: HHD- muscle strength, Balance performance - TUG, FRT, Walking performance- gaiterite and 2 min walk test

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: muscle strength, walking and balance performance
Description: HHD- muscle strength, Balance performance - TUG, FRT, Walking performance- gaiterite and 2 min walk test
Study: NCT02823106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil and Citicoline
Description: Single dosing strategy will be used.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single matching dosing strategy will be used.